登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC
ClinicalTrials.gov 上登记的一项肺癌开放试验,由山西医科大学第二医院牵头,本站收录的另外 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 2
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 牵头方山西医科大学第二医院Second Hospital of Shanxi Medical University太原医院页面
- 研究中心山西白求恩医院Shanxi Bethune Hospital太原医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06536868,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 80 岁;性别:不限
登记记录的入选字段
Confirmed small cell lung cancer of extensive stage by histology or cytology;
入选标准第 2 条
No prior antitumor treatment for extensive stage disease (if the patient has previously received chemotherapy and/or radiotherapy in the limited stage of SCLC, the treatment intent must have been curative, and there must be at least a 6-month treatment-free interval between the end of chemotherapy, radiotherapy, or chemoradiotherapy and the diagnosis of extensive stage SCLC);
入选标准第 5 条
Within 3 days prior to treatment, an ECOG score of 0 to 1;
入选标准第 4 条
Prior use of antitumor treatment targeting the PD-(L)1 pathway.
排除标准第 6 条
At least one measurable lesion by imaging studies (according to RECIST 1.1) with a long diameter of ≥10 mm as examined by spiral CT or MRI;
入选标准第 3 条
Female patients who are pregnant or breastfeeding, or women of childbearing potential with a positive baseline pregnancy test;
排除标准第 5 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:日常活动能力;化验:血常规、肝肾功能;试验排除的其他疾病。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06536868,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Patients aged between 18 to 80 years old (inclusive of 18th and 80th birthdays), male or female, at the time of signing the informed consent form; Confirmed small cell lung cancer of extensive stage by histology or cytology; At least one measurable lesion by imaging studies (according to RECIST 1.1) with a long diameter of ≥10 mm as examined by spiral CT or MRI; Within 3 days prior to treatment, an ECOG score of 0 to 1; No prior antitumor treatment for extensive stage disease (if the patient has previously received chemotherapy and/or radiotherapy in the limited stage of SCLC, the treatment intent must have been curative, and there must be at least a 6-month treatment-free interval between the end of chemotherapy, radiotherapy, or chemoradiotherapy and the diagnosis of extensive stage SCLC); Expected life span of ≥3 months; Good function of vital organs; The subject voluntarily joins this study, signs the informed consent form, has good compliance, and cooperates with follow-up.排除标准:Exclusion Criteria:
Concurrent severe respiratory diseases: such as pulmonary fibrosis; Presence of psychiatric disorders, hematologic diseases, autoimmune diseases, and severe primary diseases of the heart, brain, liver, or kidneys; Uncontrolled active infections; Known or suspected allergies to the study medication and its excipients; Female patients who are pregnant or breastfeeding, or women of childbearing potential with a positive baseline pregnancy test; Prior use of antitumor treatment targeting the PD-(L)1 pathway.
引自 ClinicalTrials.gov, NCT06536868, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06536868,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。